Macular oedema (retinal vein occlusion) - dexamethasone: review decision - January 2015
The Institute was proposing that TA229 should be moved to the static list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
Consequently, TA229 will be moved to the ‘static list’ of technology appraisals and recommendations will remain extant. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 23 January 2015